These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17288907)

  • 21. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.
    Simpson KN; Chen SY; Wu AW; Boulanger L; Chambers R; Nedrow K; Tawadrous M; Pashos CL; Haider S
    HIV Med; 2014 Sep; 15(8):488-98. PubMed ID: 24641448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.
    Brown TT; Li X; Cole SR; Kingsley LA; Palella FJ; Riddler SA; Chmiel JS; Visscher BR; Margolick JB; Dobs AS
    AIDS; 2005 Sep; 19(13):1375-83. PubMed ID: 16103768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.
    Shikuma CM; Hu N; Milne C; Yost F; Waslien C; Shimizu S; Shiramizu B
    AIDS; 2001 Sep; 15(14):1801-9. PubMed ID: 11579242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
    Stoll M; Kollan C; Bergmann F; Bogner J; Faetkenheuer G; Fritzsche C; Hoeper K; Horst HA; van Lunzen J; Plettenberg A; Reuter S; Rockstroh J; Stellbrink HJ; Hamouda O; Bartmeyer B;
    PLoS One; 2011; 6(9):e23946. PubMed ID: 21931626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.
    Nolan D; Mallal S
    Antivir Ther; 2004 Dec; 9(6):849-63. PubMed ID: 15651744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.
    Hulgan T; Haas DW; Haines JL; Ritchie MD; Robbins GK; Shafer RW; Clifford DB; Kallianpur AR; Summar M; Canter JA
    AIDS; 2005 Sep; 19(13):1341-9. PubMed ID: 16103764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
    Orkin C; Llibre JM; Gallien S; Antinori A; Behrens G; Carr A
    HIV Med; 2018 Jan; 19(1):18-32. PubMed ID: 28737291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A; Miller J; Eisman JA; Cooper DA
    AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.
    Di Biagio A; Ricci E; Viscoli C; Mesini A; Menzaghi B; Carenzi L; Orofino G; Parruti G; Martinelli C; Madeddu G; De Socio GV; Franzetti M; Quirino T; Bonfanti P;
    Curr HIV Res; 2013 Apr; 11(3):179-86. PubMed ID: 23432466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.